Morphosys, Galapagos and Novartis announced a joint decision to end the clinical development program of MOR106 in atopic dermatitis. The decision was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The analysis detected a low probability to meet the primary endpoint of the study, defined as the percentage change in the eczema area and severity index (EASI) score. The decision was based on a lack of efficacy and not on safety concerns.
The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study. All studies in atopic dermatitis will be ended. The companies plan to explore the future strategy with MOR106.
MOR106 was jointly discovered by Galapagos and MorphoSys. In July 2018, Galapagos and MorphoSys entered into an exclusive worldwide development and commercialization collaboration with Novartis with respect to MOR106.
MOR106 is a human monoclonal antibody directed against IL-17C and was generated using MorphoSys’s Ylanthia antibody platform. IL-17C is a cytokine expressed preferentially in the skin and which has been implicated in dermal inflammation and shown to be distinct from other members of the IL-17 cytokine family.